Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma

NCT02898259 is registered in ClinicalTrials.gov with Brian Hill as lead sponsor.

NCT NCT02898259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02898259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma
Lead sponsor
Brian Hill
Phase
Phase 1/2
Overall status
Terminated
Start date
February 20, 2017
Completion date
June 6, 2022
Enrollment
19 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma, lymphoma